本研究旨在评估美国前列腺癌（PC）的疾病负担，并评估与该病支出有关的关键影响因素。通过获取2019年全球疾病负担研究中PC的总死亡、发病率、患病率和残疾调整生命年，利用医疗支出面板调查估计医疗支出和生产力损失，并调查美国的支付和医疗资源使用情况。开展多元逻辑回归模型以确定影响支出的关键因素。对于50岁及以上患者，所有年龄组的负担在6年期间显示了适度的增加。2014年至2019年，年度医疗支出估计范围为248亿至392亿美元。患者的年度生产力损失约为1,200美元。医疗费用的三个主要组成部分是住院治疗、处方药和门诊就诊。医保是幸存者的最大支付来源。在药品消费方面，泌尿道药剂（57.0％）和抗肿瘤药物（18.6％）是主要治疗药物。高医疗支出与年龄（P = 0.005）、有私人医保（P = 0.016）、更多共患病、不吸烟（P = 0.001）和患者自我感知的公平/较差健康状况（P <0.001）呈正相关。从2014年到2019年，PC的国家实际数据显示美国的疾病负担继续增加，部分原因与患者特征有关。

The aim of this study was to evaluate the disease burden of prostate cancer (PC) and assess key influencing factors associated with the disease expenditures of PC in the United States (US).The total deaths, incidence, prevalence, and disability-adjusted life-years of PC were obtained from the Global Burden of Disease Study 2019. The Medical Expenditure Panel Survey was used to estimate healthcare expenditures and productivity loss and to investigate patterns of payment and use of healthcare resources in the US. A multivariable logistic regression model was conducted to identify key factors influencing expenditures.For patients aged 50 and older, the burden for all age groups showed a modest increase over the 6-year period. Annual medical expenditures were estimated to range from $24.8 to $39.2 billion from 2014 to 2019. The annual loss in productivity for patients was approximately $1,200. The top 3 major components of medical costs were hospital inpatient stays, prescription medicines, and office-based visits. Medicare was the largest source of payments for survivors. In terms of drug consumption, genitourinary tract agents (57.0%) and antineoplastics (18.6%) were the main therapeutic drugs. High medical expenditures were positively associated with age (P=0.005), having private health insurance (P=0.016), more comorbidities, not currently smoking (P=0.001), and patient self-perception of fair/poor health status (P<0.001).From 2014 to 2019, the national real-world data of PC revealed that the disease burden in the US continued to increase, which was partly related to patient characteristics.